
1. Short title
This Act may be cited as the Remote Opioid Monitoring Act of 2023. 2. Providing for a study on the effects of remote monitoring on individuals who are prescribed opioids
 (a) In general
Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall conduct a study and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Committee on Finance of the Senate a report on the use of remote monitoring with respect to individuals who are prescribed opioids.
(b) Report
The report described in subsection (a) shall include— 
(1) an assessment of scientific evidence related to the efficacy, individual outcomes, and potential cost savings associated with remote monitoring for individuals who are prescribed opioids compared to such individuals who are not so monitored;

(2) an assessment of the current prevalence of remote monitoring for individuals who are prescribed opioids, including the use of such monitoring for such individuals in other countries; and 
(3) recommendations to improve availability, access, and coverage for remote monitoring for individuals who are prescribed opioids, including through changes to Federal health care programs (as defined in section 1128B of the Social Security Act (42 U.S.C. 1320a–7b)) and, if determined appropriate by the Comptroller General, an identification of cohorts of individuals who stand to benefit the most from remote monitoring when prescribed opioids. 
